Using bioparticles to target and attack tumor metastases in aggressive breast cancer
Nucleocapsid bioparticles eliciting multi-pronged attack on tumor metastases
This study is exploring new ways to use special particles to help fight the spread of triple negative breast cancer, especially in patients whose cancer has reached the brain and other organs, with the hope of offering better treatment options for those who have few choices right now.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cedars-Sinai Medical Center NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project ID | NIH-10782528 on NIH RePORTER |
What this research studies
This research focuses on developing innovative bioparticles that can effectively target and combat tumor metastases, particularly in patients with triple negative breast cancer (TNBC), which is known for its aggressive nature and poor prognosis. The approach involves utilizing the unique properties of adenovirus proteins to create a multi-faceted attack on cancer cells, especially those that have spread to the brain and other organs. By enhancing the ability of treatments to cross the blood-brain barrier, this research aims to provide new therapeutic options for patients who currently have limited treatment choices due to the aggressive nature of their cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with triple negative breast cancer, particularly those with metastatic disease.
Not a fit: Patients with non-metastatic breast cancer or those with other subtypes of breast cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with metastatic triple negative breast cancer, potentially improving survival rates and quality of life.
How similar studies have performed: While the approach of using bioparticles for cancer treatment is innovative, similar strategies targeting tumor metastases have shown promise in preliminary studies, indicating potential for success.
Where this research is happening
Los Angeles, United States
- Cedars-Sinai Medical Center — Los Angeles, United States (Active)
Researchers
- Principal investigator: Medina-Kauwe, Lali K — Cedars-Sinai Medical Center
- Study coordinator: Medina-Kauwe, Lali K
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.